FDA Clears Amgen-Allergan Biosimilar Of Genentech's Avastin
The U.S. Food and Drug Administration on Thursday cleared Amgen Inc. and Allergan Inc.'s biosimilar version of Genentech Inc.'s blockbuster Avastin, marking the first copycat biologic treatment for cancer and the...To view the full article, register now.
Already a subscriber? Click here to view full article